Press Release

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

BIG and World Cancer Day – Together, all our actions matter

OlympiA adjuvant trial results show olaparib for BRCA 1/2 mutated and high-risk early breast cancer reduced recurrence risk by 42%

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

Breast International Group’s new Executive Board

First results of the European AURORA study: towards a better understanding of the molecular changes driving metastatic breast cancer

Metastatic breast cancer, an ultramarathon

First results of MA.32 trial: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals

World Cancer Day 2022: the DECRESCENDO study

OlympiA trial – olaparib reduces risk of death by 32% in patients with a specific breast cancer profile